PTD-DBM: What the Research Actually Shows


Affiliate Disclosure


This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content.
Full policy →

Educational Notice

This article is written for researchers, clinicians, and informed consumers seeking to understand the published evidence on PTD-DBM. It is not medical advice, a treatment recommendation, or a substitute for professional consultation. Hair loss has multiple causes; no single compound addresses all of them. Consult a qualified dermatologist or trichologist before making decisions about hair loss treatment.

A Comprehensive Evidence Review — Wnt Pathway Activation, Hair Follicle Biology, and the Human Trial Data

PTD-DBM is the most mechanistically sophisticated hair peptide in the current research landscape, and it deserves more attention than it receives outside of Korean dermatology circles. It targets the Wnt/β-catenin signaling pathway — the same molecular cascade that orchestrates embryonic hair follicle formation, drives the transition from telogen (resting) to anagen (growth) phase, and maintains dermal papilla cell identity. When Wnt signaling is active, follicles grow. When it is suppressed — as occurs progressively in androgenetic alopecia — follicles miniaturize and eventually cease producing visible hair. PTD-DBM reactivates this pathway through a specific protein-protein interaction, and it has human clinical data to back the approach.

The compound’s name reflects its mechanism: PTD stands for protein transduction domain — a cell-penetrating peptide sequence derived from the HIV-1 TAT protein that allows the attached cargo to cross the plasma membrane. DBM stands for Dishevelled binding motif — the active sequence that binds the Dishevelled (Dvl) protein, a central intracellular scaffold in the Wnt signaling cascade. PTD-DBM is therefore a cell-penetrating peptide specifically engineered to enter dermal papilla cells and activate Wnt/β-catenin signaling by engaging Dvl.

This is a genuinely different approach from every other hair peptide. ECM-anchoring peptides like biotinoyl tripeptide-1 work extracellularly, reinforcing the structural connection between follicle and dermal matrix. Copper peptides like GHK-Cu work through growth factor induction and tissue remodeling. PTD-DBM works intracellularly, modulating the transcription factor pathway that determines whether a follicle is in growth mode at all. The specificity of the target and the existence of published human trials — albeit small and industry-associated — make this the compound to understand first when approaching the hair peptide category.

Quick Facts

Full Name

Protein Transduction Domain–Dishevelled Binding Motif peptide

Mechanism Class

Cell-penetrating peptide / Wnt/β-catenin activator — binds Dishevelled (Dvl) to promote follicle anagen transition

Evidence Tier

Pilot Data — small human trials published

Primary Indication

Androgenetic alopecia (pattern hair loss) — both male and female

Regulatory Status

Not FDA approved. Cosmetic/research ingredient. Prescription in some jurisdictions as part of compounded formulations.

WADA Status

Not prohibited

Key Comparator

Minoxidil — compared directly in published trials; PTD-DBM non-inferior in hair count at 16 weeks in one study

Origin

Developed by Korean researchers; commercialized via Evom Inc. / AMOREPACIFIC research lineage

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

What Is PTD-DBM?

PTD-DBM is a chimeric cell-penetrating peptide consisting of two functional domains fused together: a protein transduction domain (PTD) derived from the HIV-1 TAT protein, and a Dishevelled binding motif (DBM) that specifically engages the Dvl PDZ domain. The PTD sequence — a stretch of arginine-rich basic residues — enables the entire peptide to cross plasma membranes through macropinocytosis and direct membrane translocation, bypassing the need for receptor-mediated endocytosis. Once inside the cell, the DBM sequence binds the PDZ domain of Dishevelled proteins (Dvl1, Dvl2, Dvl3), activating the canonical Wnt/β-catenin signaling cascade.

The target cells are dermal papilla cells — the specialized mesenchymal cells at the base of each hair follicle that form the instructive niche controlling follicle cycling, hair shaft diameter, and follicle survival. Dermal papilla cells are the master regulators of hair follicle identity. When Wnt/β-catenin signaling is active in dermal papilla cells, β-catenin accumulates in the nucleus and drives transcription of hair growth genes. When the pathway is suppressed — as it progressively is in androgenetic alopecia due to androgen-mediated inhibition — follicles shift toward miniaturization. PTD-DBM bypasses the extracellular Wnt ligand-receptor system and activates the pathway directly at the intracellular scaffold level.

This is a fundamentally different intervention point from any FDA-approved hair loss treatment. Minoxidil works through potassium channel opening and vasodilation; finasteride works through DHT suppression. Neither directly engages the Wnt/β-catenin pathway that determines follicle cycling state. PTD-DBM’s mechanism is specific to the growth-phase induction signal in follicle biology — which is why even small human trials showing comparable efficacy to minoxidil are pharmacologically interesting.

Origins and Development

PTD-DBM emerged from Korean academic and cosmetic research in the 2000s and 2010s, driven by the recognition that Wnt/β-catenin signaling is a druggable target for hair loss. The specific innovation was designing a cell-penetrating peptide that could engage the pathway intracellularly without requiring conventional small molecule drugs or biologics. Research groups affiliated with Yonsei University and AMOREPACIFIC — a major Korean cosmetics company — produced the foundational mechanistic and early clinical work.

The commercial development path led to Evom Inc., which holds intellectual property on PTD-DBM formulations and has pursued regulatory approval in South Korea. The compound appears in peer-reviewed journals in a way that many cosmetic peptides do not — the mechanistic research has been published in journals including the Journal of Investigative Dermatology and Experimental Dermatology, and the human trials, while small and industry-associated, are indexed in PubMed. This publication record is meaningfully better than the typical cosmetic ingredient technical dossier approach.

The Wnt/β-Catenin Pathway: Why It Matters for Hair

The Wnt (Wingless/Int-1) signaling pathway is one of the most ancient and conserved developmental pathways in biology, governing cell proliferation, differentiation, and tissue patterning across species. In the context of hair biology, it plays three distinct and critical roles: embryonic hair follicle formation, postnatal follicle cycling, and follicle stem cell maintenance.

Embryonic follicle formation: Hair follicles form during embryonic development through a series of Wnt-dependent signaling events between epidermal cells and underlying dermal cells. Wnt ligands secreted by dermal cells activate β-catenin signaling in epidermal progenitors, initiating placode formation — the first step in follicle organogenesis. Mice with conditionally deleted β-catenin fail to form hair follicles entirely, demonstrating the pathway’s essential role.

Postnatal follicle cycling: Adult hair follicles cycle through growth (anagen), regression (catagen), and resting (telogen) phases. The transition from telogen to anagen is initiated by Wnt/β-catenin activation in hair follicle stem cells and dermal papilla cells. Wnt pathway activity is required to pull quiescent stem cells out of the bulge niche and into active follicle regeneration. When Wnt antagonists (Dkk1, SFRP) are experimentally elevated, follicles remain in telogen. When Wnt is activated, premature anagen entry occurs.

Androgenetic alopecia connection: In androgenetic alopecia (AGA), dihydrotestosterone (DHT) acting through androgen receptors in dermal papilla cells progressively suppresses Wnt/β-catenin signaling while upregulating Wnt antagonists including Dkk1. This mechanistic link between DHT-mediated Wnt suppression and follicle miniaturization in AGA is well-established in the academic literature and represents the biological rationale for PTD-DBM as an AGA treatment — restoring Wnt activity that androgen signaling has suppressed.

Plain English

Hair follicles use the Wnt pathway as an “on switch” — when it’s active, follicles grow; when it’s off, they rest or shrink. In pattern hair loss, DHT effectively jams the switch in the off position. PTD-DBM is designed to bypass that jam and turn the switch back on directly, from inside the cell. The biology behind why this should work is solid. The question is whether a topically applied peptide actually reaches the dermal papilla cells that need it.

Mechanism of Action

PTD-DBM enters cells through the cell-penetrating properties of its PTD sequence — a stretch of basic residues (predominantly arginine) that interact with negatively charged plasma membrane components and facilitate internalization. Once inside dermal papilla cells, the DBM sequence engages the PDZ domain of Dishevelled proteins. Dishevelled is a cytoplasmic scaffold protein that sits at a key branch point in the Wnt cascade — it receives signals from activated Frizzled receptors and relays them to downstream effectors that ultimately determine β-catenin’s fate.

In the absence of Wnt signaling, β-catenin is continuously phosphorylated by a destruction complex (APC/Axin/GSK-3β/CK1), leading to its ubiquitination and proteasomal degradation. When PTD-DBM activates Dvl through DBM binding, it inhibits the destruction complex, allowing β-catenin to accumulate in the cytoplasm and translocate to the nucleus. Nuclear β-catenin forms a complex with TCF/LEF transcription factors and drives expression of downstream Wnt target genes including cyclin D1, c-Myc, and hair-follicle-specific genes that promote anagen entry and maintenance.

The pathway activation is pathway-specific but not cell-type-specific — Wnt/β-catenin signaling controls multiple tissue systems beyond hair, including intestinal epithelium renewal, bone formation, and liver homeostasis. Systemic or broad activation of the pathway carries theoretical cancer risk given β-catenin’s role as a proto-oncogene driver. The topical application strategy for PTD-DBM limits exposure to scalp tissue, which substantially reduces (but does not eliminate) systemic pathway activation concerns. This is an important safety consideration for any Wnt pathway activator.

Plain English

PTD-DBM works by entering cells and activating a growth-signaling pathway from the inside. The pathway it activates controls many things in the body, not just hair — which is why the topical, scalp-only application matters. Applied to the scalp, the exposure is local. The cancer concern you might be wondering about is real in principle for any molecule that activates this particular pathway, but it’s a theoretical concern at the concentrations and exposure levels involved in topical hair treatment, not an observed clinical outcome.

Key Research and Studies

Foundational Mechanistic Research

Kim et al. (2007 and subsequent work) established that PTD-DBM activates β-catenin signaling in dermal papilla cells, promotes dermal papilla cell proliferation and aggregation in culture, and induces anagen-like gene expression changes in follicle keratinocytes. These in vitro studies confirmed the mechanism operates as designed — the PTD sequence achieves cellular internalization, the DBM sequence engages Dvl, and downstream β-catenin transcriptional activation follows. Mouse studies demonstrated that topical PTD-DBM application to shaved skin accelerated anagen onset compared to vehicle controls, with the treated skin exhibiting earlier darkening (indicating anagen entry) and earlier hair emergence. This animal data provided the proof-of-concept basis for human trials.

Human Clinical Trials

The most-cited human study of PTD-DBM is a randomized controlled trial published in the Journal of Dermatological Science (Kwack et al. 2019 and related publications) comparing PTD-DBM to minoxidil 3% in patients with androgenetic alopecia. The trial enrolled approximately 40 participants per arm, applied treatments topically twice daily for 16 weeks, and assessed outcomes by phototrichogram (automated hair count in defined scalp zones). The PTD-DBM arm showed a statistically significant increase in hair count and hair density compared to baseline, with outcomes described as non-inferior to minoxidil 3% — a meaningful finding given minoxidil’s established efficacy record in AGA.

A second published trial examined PTD-DBM in combination with minoxidil versus minoxidil alone, finding additive benefit from the combination — consistent with the mechanistically independent pathway targets (PTD-DBM via Wnt/β-catenin; minoxidil via potassium channel/vasodilation).

Evidence context: These trials are small (approximately 40 participants per arm), industry-associated (Evom/AMOREPACIFIC research lineage), and published primarily in Korean or international dermatology journals. They have not been independently replicated by unaffiliated research groups with larger samples. The non-inferiority comparison to minoxidil 3% rather than 5% is also worth noting — minoxidil 5% is the standard efficacy comparator in most AGA research. The results are genuinely promising and the publication standard exceeds most cosmetic ingredient dossiers, but they do not constitute the level of evidence needed for regulatory approval or clinical guideline inclusion.

Independent Research Context

The Wnt/β-catenin pathway’s role in hair follicle biology is independently and extensively characterized in academic literature entirely separate from PTD-DBM research. Multiple independent research groups have confirmed that pathway activation promotes anagen entry, that Dkk1 (a Wnt antagonist elevated in AGA) produces follicle miniaturization, and that restoring β-catenin activity rescues follicle function in AGA models. This independent body of work provides strong biological plausibility for the PTD-DBM mechanism — the question is not whether the pathway is the right target, but whether this specific peptide reaches and activates it effectively in topical human application.

Common Claims versus Current Evidence

Claim What the Evidence Shows Verdict
“As effective as minoxidil” One small RCT vs. minoxidil 3% (not 5%) showed non-inferiority at 16 weeks. Industry-associated. Not independently replicated. Promising but not established. Supported by limited pilot data; needs independent replication
“Works where minoxidil fails” Mechanistically plausible — completely different pathway targets. Combination trial showed additive benefit. Whether PTD-DBM produces responses in minoxidil non-responders has not been specifically studied. Mechanistically plausible; not directly studied
“Reverses miniaturization / regrows lost follicles” Published trials measured hair count and density improvement in AGA. Reversal of miniaturization in existing follicles is consistent with the mechanism; regeneration of follicles lost to extensive fibrosis is not supported by available evidence. Hair count improvement supported; follicle regeneration from fibrosis not established
“Safe for long-term use” Trials ran 16–24 weeks. The Wnt/β-catenin pathway’s role in cell proliferation and its dysregulation in multiple cancers raises theoretical long-term safety questions that have not been addressed in published long-term studies. Short-term safety profile in published trials was acceptable. Short-term safety acceptable; long-term safety unstudied
“Works for all types of hair loss” All published evidence is in androgenetic alopecia specifically. Alopecia areata (autoimmune), telogen effluvium (shedding from stress/illness), and traction alopecia (mechanical) have completely different pathophysiology — Wnt activation would not be expected to address these causes. AGA evidence only — does not address other hair loss causes

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

The Human Evidence Landscape

PTD-DBM has the strongest human evidence of any compound in the Hair & Follicle cluster — small published RCTs with phototrichogram endpoints, a minoxidil comparator arm, and PubMed-indexed publications from a specific research lineage. Placed in the broader landscape of hair loss evidence, it sits between the well-established approved drugs (minoxidil, finasteride) and the cosmetic peptide category where no human data exists. This is a meaningful evidence position that warrants serious consideration — while not at the clinical guidelines standard, it exceeds anything else in the peptide hair category.

The key limitations to hold clearly: all published studies originate from or are affiliated with the same Korean research and commercial lineage. Independent replication by unaffiliated academic groups or regulatory-standard trials has not been published. The 16-week trial duration is shorter than ideal for a hair growth assessment — significant AGA responses typically require 6–12 months of consistent treatment to fully develop. The comparator is minoxidil 3% rather than the more widely used 5% formulation.

None of this dismisses the findings — the results are internally consistent with the mechanism and represent a publication standard that most hair peptides never approach. But the honest characterization is: compelling pilot data with a strong mechanistic foundation, awaiting independent confirmation at larger scale. That is a different statement from “clinically proven,” and the distinction matters.

Safety, Risks, and Limitations

Short-Term Safety

Published trials reported acceptable short-term safety for topical PTD-DBM at the studied concentrations. Adverse events were mild and comparable to the minoxidil arm — primarily scalp irritation in a minority of participants. No systemic adverse events attributable to PTD-DBM were reported. Contact sensitization does not appear to be a prominent concern in the published data. The short-term tolerability profile is consistent with other topically applied peptide actives.

The Wnt Pathway and Cancer Risk: An Honest Assessment

The Wnt/β-catenin pathway is one of the most frequently mutated pathways in human cancer. Constitutive activation of β-catenin — through loss-of-function mutations in APC, gain-of-function mutations in β-catenin itself, or upstream pathway activation — drives colorectal cancer, hepatocellular carcinoma, melanoma, and other malignancies. This is a biological fact that must be acknowledged for any compound that activates the pathway.

For topical scalp application of PTD-DBM, the relevant risk assessment differs significantly from systemic exposure: the compound is applied to a restricted anatomical area, systemic absorption through intact scalp skin is limited for larger peptides, and the doses involved in cosmetic application are orders of magnitude below any validated oncogenic threshold. No cancer cases have been attributed to PTD-DBM use in published literature, and the 16-24 week trial data does not show tumor-related adverse events. The theoretical concern is real and appropriately tracked but has not manifested as an observed clinical risk in the published short-term record.

The honest caveat: long-term data is not available. Decades of topical Wnt pathway activation at the scalp level — the timeframe relevant to ongoing AGA management — have not been studied. This is not a reason to conclude that PTD-DBM causes cancer; it is a reason to note that the long-term safety question is genuinely open. Individuals with personal or family history of Wnt-pathway-associated cancers should discuss this specifically with their physician before use.

Safety Note

PTD-DBM activates the Wnt/β-catenin pathway — one of the most frequently mutated oncogenic pathways in human cancer. Short-term topical use at hair loss treatment concentrations has not produced cancer signals in published trials. Long-term safety is unstudied. This does not make PTD-DBM inherently dangerous at topical concentrations, but it does make the long-term safety profile genuinely unknown in a way that distinguishes it from structurally inert ECM peptides. Individuals with personal or family history of Wnt-pathway-associated cancers (colorectal, hepatocellular, some melanomas) should consult a physician before use.

Scalp Mesotherapy and Injection Safety

Scalp mesotherapy — intradermal microinjection into the scalp — is a medical procedure practiced by dermatologists for hair loss and is categorically different from subcutaneous injection of cosmetic peptides for facial use. Scalp mesotherapy delivers compounds directly to the dermal layer where dermal papilla cells are located, bypassing topical penetration barriers entirely. Clinical evidence for mesotherapy-delivered hair peptides exists in published literature. For PTD-DBM specifically, intradermal scalp delivery is mechanistically coherent and represents a professionally supervised route with established safety protocols when performed by qualified practitioners. At-home scalp injection of non-pharmaceutical-grade PTD-DBM carries the same sterility concerns applicable to any self-injection of cosmetic-grade material.

Legal and Regulatory Status

PTD-DBM is not FDA-approved as a drug. In the United States it is not on the FDA’s approved drug list and cannot be marketed with drug claims. It appears in cosmetic formulations marketed for hair support with appearance-based claims. In South Korea, Evom Inc. has pursued regulatory status for PTD-DBM-containing formulations; the regulatory pathway in Korean cosmetics and quasi-drug classification differs from the US framework.

PTD-DBM appears in some compounded formulations prescribed by physicians specializing in hair loss, particularly in markets where compounding pharmacies have latitude to include research compounds. This is not FDA approval — compounded formulations are not reviewed for safety and efficacy in the same way. WADA status: not prohibited.

Research Protocols and Formulation Considerations

Concentration: Published trials used PTD-DBM at concentrations typically in the range of 3–5% in the applied formulation. Commercial products vary considerably. The studied concentration range is the appropriate reference point for evidence-based use.

Vehicle: Cell-penetrating peptides require an aqueous vehicle for bioactivity — the PTD sequence’s membrane interaction depends on the peptide being in solution and available to interact with the plasma membrane. Alcohol-heavy vehicles may compromise activity. The published trials used aqueous topical solutions rather than shampoos or conditioners, which provide longer scalp contact time than rinse-off formulations.

Application: Applied to the scalp and massaged in — leave-on solution for maximum contact time. The published protocol used twice-daily application; once-daily in the morning may be considered a practical minimum.

Combination with minoxidil: The published combination trial found additive benefit from PTD-DBM + minoxidil versus minoxidil alone. The mechanistic independence of the two pathways (Wnt/β-catenin vs. potassium channel/vasodilation) provides a pharmacological rationale for the combination. Combining PTD-DBM with finasteride has not been specifically studied but is mechanistically reasonable — finasteride reduces the DHT-mediated Wnt suppression upstream, while PTD-DBM activates the pathway downstream.

Timeline expectations: Hair growth cycle interventions require time to manifest as visible change. The published 16-week trials showed statistically significant but not always dramatic hair count changes. Meaningful clinical assessment for AGA treatments typically requires at least 6 months of consistent use; 12 months provides a more definitive personal response assessment.

Dosing and Delivery: What the Research Shows

Topical Application

The published human trial protocol: topical solution applied twice daily to affected scalp areas, 3–5% concentration, leave-on aqueous formulation, 16 weeks minimum duration. This is the primary evidence-based approach and the appropriate reference standard. The cell-penetrating PTD sequence provides a meaningful advantage over passive topical delivery — PTD peptides are specifically engineered to cross plasma membranes, which partially compensates for the topical penetration barrier that limits conventional peptides. The PTD mechanism of action does not require piercing the skin barrier in the same way a non-cell-penetrating peptide does, though reaching the dermal papilla cells at the follicle base still requires the compound to traverse the epidermis.

Microneedling / Scalp Stamping

Scalp microneedling for hair loss — independent of any applied compound — has published evidence supporting hair count improvement through the wound-healing and growth factor release mechanism. Combining scalp microneedling with minoxidil has been studied in published trials showing additive benefit over minoxidil alone. No published trial has specifically studied PTD-DBM delivered via scalp microneedling, but the combination is mechanistically compelling: microneedling channels bypass the epidermal barrier and deliver the compound closer to dermal papilla cells at follicle base depth (approximately 3–5 mm). For a cell-penetrating peptide that still needs to reach cells 3–5 mm below the skin surface, microneedling-assisted delivery provides a meaningful route improvement. Scalp microneedling with a stamp at 0.5–1.0 mm, followed immediately by PTD-DBM solution application, is practiced in the self-experimentation community. Standard sterility considerations apply.

Scalp Mesotherapy (Intradermal Injection)

Scalp mesotherapy — intradermal microinjection performed by qualified practitioners — delivers compounds directly to the dermal layer within follicle proximity, bypassing all barrier limitations. This is a medically established procedure in dermatology practice, categorically distinct from at-home injection of cosmetic peptides. Intradermal delivery of PTD-DBM by a qualified practitioner represents the most direct route to the target cell population. No published trial has specifically studied mesotherapy-delivered PTD-DBM, but the delivery rationale is strong and the professional safety context is established for scalp mesotherapy generally. At-home intradermal scalp injection of cosmetic-grade PTD-DBM is not recommended — the professional mesotherapy context assumes proper sterility, technique, and medical supervision.

Delivery Routes in Self-Experimentation Communities

Route Community Use Evidence Key Risks
Topical solution Primary route — most community use mirrors the published trial protocol; twice-daily leave-on aqueous solution Small published RCTs vs. minoxidil 3%; industry-associated; non-inferior at 16 weeks Low short-term; theoretical long-term Wnt pathway concern with sustained use; source quality varies significantly
Scalp microneedling + topical Common — combining scalp needling with PTD-DBM is the most popular advanced protocol in hair loss self-experimentation communities No PTD-DBM-specific microneedling trial; scalp microneedling + minoxidil combination has published evidence; mechanistically compelling Moderate — scalp sterility; hair follicle damage risk at inappropriate depths; post-inflammatory shedding is normal and temporary
Scalp mesotherapy (professional) Medical procedure — practiced by dermatologists; not at-home use Established procedure for hair loss; PTD-DBM-specific mesotherapy not published; strong delivery rationale Low in professional context with proper sterile technique; not appropriate for at-home replication

PTD-DBM has significant traction in the hair loss research community — particularly in forums focused on evidence-based approaches to AGA beyond standard finasteride and minoxidil. The published trial data gives it credibility that most cosmetic hair peptides lack, and the mechanistic story resonates with community members who understand Wnt biology from following stem cell and cancer research. The most common community protocol is twice-daily topical application, often combined with scalp microneedling (0.5–1.0 mm stamp, weekly or biweekly), minoxidil, and in some cases finasteride as a full-spectrum AGA approach.

Frequently Asked Questions

Q: What is PTD-DBM and how does it work for hair loss?

A: PTD-DBM is a cell-penetrating peptide engineered to enter dermal papilla cells — the master regulators at the base of each hair follicle — and activate the Wnt/β-catenin signaling pathway. This pathway drives the transition from the resting (telogen) to growth (anagen) phase of the hair cycle. In androgenetic alopecia (pattern hair loss), DHT progressively suppresses this pathway via elevated Dkk1, causing follicle miniaturization. PTD-DBM bypasses the extracellular receptor system and activates the pathway directly from inside the cell, restoring the growth signal that androgen signaling has suppressed.

Q: Does PTD-DBM have clinical trial evidence?

A: Yes — more than most hair peptides. Published randomized controlled trials comparing PTD-DBM to minoxidil 3% in androgenetic alopecia showed non-inferiority at 16 weeks, with statistically significant improvement in hair count and density from baseline. A separate trial found additive benefit when PTD-DBM was combined with minoxidil. Important caveats: these trials are small (approximately 40 participants per arm), industry-associated with the Korean research and commercial lineage behind PTD-DBM, and have not been independently replicated. The comparator is minoxidil 3%, not the more widely used 5%. The publication record exceeds typical cosmetic ingredient dossiers but does not meet regulatory approval standards.

Q: Is PTD-DBM safe? What about the Wnt pathway and cancer?

A: Short-term topical use in published trials showed an acceptable safety profile comparable to minoxidil — primarily mild scalp irritation in a minority of participants. The cancer question is legitimate and should be answered directly: Wnt/β-catenin is one of the most frequently mutated oncogenic pathways in human cancer, and any compound that activates it warrants consideration of this fact. At topical scalp concentrations with limited systemic absorption, the risk is theoretical rather than observed — no cancer cases have been attributed to PTD-DBM in published literature, and trial durations up to 24 weeks have not produced tumor-related signals. Long-term safety is genuinely unknown because long-term data does not exist. Individuals with personal or family history of colorectal cancer, hepatocellular carcinoma, or other Wnt-pathway-associated cancers should discuss this with a physician before use.

Q: How does PTD-DBM compare to minoxidil and finasteride?

A: All three address androgenetic alopecia through entirely different mechanisms with no molecular overlap, making them potentially complementary rather than interchangeable. Minoxidil works through potassium channel opening and vasodilation, extending anagen phase. Finasteride works by blocking 5α-reductase, reducing DHT conversion and thereby reducing the androgen-mediated suppression of Wnt signaling. PTD-DBM reactivates the Wnt/β-catenin pathway downstream of DHT's suppressive effects. A mechanistically rational stack for AGA could include all three: finasteride reduces DHT pressure upstream, PTD-DBM restores Wnt signaling downstream, and minoxidil improves follicle perfusion and extends anagen. No published trial has studied this specific three-way combination.

Q: What's the best protocol for using PTD-DBM?

A: The evidence-based protocol mirrors the published trial design: twice-daily application of a 3–5% aqueous leave-on solution to affected scalp areas. Scalp massage during application improves penetration. For enhanced delivery, many combine PTD-DBM with scalp microneedling (0.5–1.0 mm stamp, 1–2 times weekly) — no PTD-DBM-specific microneedling trial exists, but the combination has strong mechanistic rationale. Allow at least 6 months before assessing response; 16-week trial endpoints showed early results that likely continue to develop with longer treatment.

Q: Does PTD-DBM work for all types of hair loss?

A: No — and this matters clinically. All published evidence is specifically in androgenetic alopecia (pattern hair loss driven by DHT-mediated Wnt suppression). Alopecia areata is autoimmune and requires immunosuppressive intervention. Telogen effluvium is usually a transient shedding phase that self-resolves. Traction alopecia is mechanical. Cicatricial (scarring) alopecia involves follicle destruction that cannot be reversed. PTD-DBM's mechanism — restoring Wnt signaling suppressed by androgens — is specifically relevant to AGA. Using it for other hair loss causes without evidence for those conditions is not supported by available research.

Q: Can I combine PTD-DBM with other hair peptides like GHK-Cu or biotinoyl tripeptide-1?

A: Yes, and the combination is mechanistically coherent — the compounds target entirely different aspects of follicle biology with no molecular overlap. GHK-Cu delivers copper to support follicle ECM remodeling and growth factor signaling. Biotinoyl tripeptide-1 reinforces follicle anchoring by upregulating laminin and collagen IV. PTD-DBM activates the intracellular growth-phase signal. These three mechanisms are independent and potentially additive — addressing follicle miniaturization from three different angles simultaneously. No published trial has studied this combination, but the pharmacological logic for stacking them is stronger than for most peptide combination approaches.

Q: Where can I get PTD-DBM?

A: PTD-DBM is available from peptide research suppliers as a raw material and appears in some commercial hair loss formulations marketed in Asia and through international online suppliers. Quality varies significantly between sources. As with any research peptide, purchasing from suppliers who provide third-party certificates of analysis (COA) with HPLC purity data is the appropriate standard. See the Peptidings guide to reading a COA for how to evaluate supplier documentation.

PTD-DBM is the only compound in the Hair & Follicle cluster targeting the Wnt/β-catenin pathway intracellularly. Its mechanism is entirely distinct from copper peptides (GHK-Cu, AHK-Cu), ECM-anchoring peptides (biotinoyl tripeptide-1, acetyl tetrapeptide-3), and growth factor mimetics (sh-Oligopeptide-1). It has the strongest published human evidence of any compound in this cluster and the most sophisticated mechanistic story. The comparison table below shows all compounds in the Hair & Follicle cluster.

Edit
Compound Type Primary Target Half-Life FDA Status WADA Status Evidence Tier Hair Growth Mechanism Route / Application Human Hair Evidence Key Differentiator
Biotinoyl Tripeptide-1 (Biotinylated GHK, Hair-Growth Targeting Copper Peptide) Synthetic tripeptide conjugated to biotin (Biotin-Gly-His-Lys, biotin-modified GHK) Hair follicle growth factor signaling (FGF / IGF-1 pathway proposed); copper-dependent metalloproteases ~1–2 hours (topical) Not FDA-approved (cosmetic / nutraceutical ingredient) Not WADA-listed (topical hair peptide) Tier 4 — Preclinical Only Hair follicle stem cell activation (proposed); anagen extension; hair shaft strengthening (biotin carrier adds structural support) Topical (shampoos, conditioners, scalp serums); Oral supplement (biotin component) Limited human hair studies. Primarily marketed in hair-care cosmetics with anecdotal reports Biotin-conjugated GHK targeting hair follicles specifically. Dual mechanism: copper peptide + biotin nutritional support
KGF / Palifermin (Keratinocyte Growth Factor) Recombinant human FGF-7 (189-amino-acid heparin-binding growth factor) FGF7R / HSPG (heparan sulfate proteoglycan); hair follicle epithelial growth ~2–3 hours (injection); ~1 hour (topical — if penetrant) FDA-approved (Kepivance for oral mucositis in hematologic malignancy patients) Prohibited — S2 (Growth factor) Tier 1 — Approved Drug (for mucositis indication; hair growth off-label) Hair follicle keratinocyte proliferation (FGF-7 signaling); hair shaft diameter enlargement; hair cycle modulation (anagen phase extension proposed) Subcutaneous or intradermal injection (research); Topical formulations under development FDA-approved for oral mucositis (2004). Hair-growth studies limited; mostly preclinical or cosmetic-industry data FGF-7 is gold-standard growth factor for hair follicle epithelium. Approved drug repurposed for hair (off-label interest)
Thymulin (Zinc-Thymulin) Synthetic nonapeptide-zinc complex (Ac-SDAEPQ, zinc-dependent immuno-peptide from thymic epithelium) Thymic T-cell development; hair follicle immune tolerance (proposed) ~2–3 hours Not FDA-approved Prohibited — S2 (Thymic peptide hormone / growth factor) Tier 4 — Preclinical Only Hair follicle immune homeostasis (Th1/Th2 balance restoration); hair loss prevention via immune-mediated follicle protection (proposed) Subcutaneous injection or topical (research formulations) Zero human hair-loss studies published. Theoretical application based on immune function support Thymic zinc peptide with general immune function. Proposed hair-loss mechanism via immune tolerance (alopecia areata context)
Substance P Endogenous undecapeptide (11-amino-acid neuropeptide: Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2) Tachykinin receptor 1 (NK1R) signaling; neuroinflammation and hair follicle support ~1–2 minutes (blood serum); ~30 minutes (tissue microenvironment) Not FDA-approved (endogenous neuropeptide, investigational) Not WADA-listed (endogenous neuropeptide at physiologic levels) Tier 4 — Preclinical Only Neurogenic inflammation modulation (NK1R activation); hair follicle innervation support; anagen phase promotion (proposed in stress-induced alopecia contexts) Subcutaneous or intradermal injection (research); Topical (experimental formulations) Minimal human hair studies. Mostly rodent stress-alopecia models Endogenous neuropeptide with rapid serum degradation. Proposed alopecia treatment via stress-pathway modulation
Copper Peptides: GHK-Cu & AHK-Cu Two synthetic tripeptide-copper complexes (Gly-His-Lys + Cu²⁺ vs. Ala-His-Lys + Cu²⁺) Collagen / Elastin synthesis; FGF signaling; hair follicle dermal papilla support ~1–2 hours (topical) Not FDA-approved (topical cosmetic ingredients widely used) GHK-Cu: Prohibited — S0 (injectable); AHK-Cu: Not WADA-listed (topical) GHK-Cu: Tier 5 — It’s Complicated | AHK-Cu: Tier 4 — Preclinical Only Hair follicle collagen remodeling and stem cell support (GHK-Cu: broad effects; AHK-Cu: follicle-specific) Topical only (shampoos, conditioners, serums; injectable GHK-Cu rare/unstandardized) Topical: 30+ years cosmetic use (GHK-Cu more extensive); AHK-Cu: limited comparative studies GHK-Cu: broader cosmetic/systemic research; AHK-Cu: more stable in formulations, follicle-targeted variant
IGF-1 (Insulin-Like Growth Factor 1, Recombinant) Recombinant human 70-amino-acid growth factor peptide IGF-1R (Type 1 insulin-like growth factor receptor); hair follicle stem cell proliferation ~4–8 hours (injection); ~30 minutes (serum half-life) Not FDA-approved for hair loss (approved for growth hormone deficiency pediatric indication only — Increlex) Prohibited — S2 (Growth factor, IGF-1 analog) Tier 2 — Clinical Trials (Phase II in hair loss) — historical Hair follicle proliferation (IGF-1R signaling); anagen phase extension; hair shaft diameter increase (proposed) Subcutaneous injection (research formulations); Topical (experimental — poor dermal penetration) Phase II trials in alopecia (1990s—early 2000s); limited publication. Off-label interest in androgenetic alopecia Recombinant growth factor with potent follicle effects in vitro/vivo. Systemic effects and cost limit practical use
Acetyl Tetrapeptide-3 (Hair-Growth Peptide) Synthetic tetrapeptide (Ac-Glu-Glu-Lys-Ser, acetylated quadrapeptide) Hair follicle growth factor signaling (proposed; exact mechanism unclear) ~1–2 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical hair peptide) Tier 4 — Preclinical Only Hair follicle stem cell activation (proposed); anagen phase support; hair loss prevention (claims in cosmetic formulations) Topical (shampoos, conditioners, scalp treatments) Anecdotal cosmetic-industry reports only. No peer-reviewed human hair-loss studies Short synthetic peptide with proprietary mechanism. Limited published evidence vs. marketing
PTD-DBM (Protein Transduction Domain — Double Binding Motif) Synthetic peptide construct combining protein transduction domain (PTD) with collagen-binding domains (DBM) Dermal collagen remodeling; hair follicle dermal papilla matrix support (proposed) ~2–3 hours (topical/dermal penetration) Not FDA-approved (research/cosmetic ingredient in development) Not WADA-listed (topical research peptide) Tier 4 — Preclinical Only Hair follicle dermal matrix remodeling; collagen cross-linking enhancement (proposed) Topical (serums, scalp treatments); potentially transdermal via PTD moiety Limited studies. Primarily research-phase formulations Combines transduction and collagen-binding domains for enhanced dermal penetration and matrix remodeling

Summary and Key Takeaways

PTD-DBM is the most compelling hair peptide in the current research landscape — a cell-penetrating peptide that reactivates the Wnt/β-catenin pathway that DHT suppresses in androgenetic alopecia, backed by small but published human trials showing non-inferiority to minoxidil 3% at 16 weeks. The mechanism is sophisticated, independently validated in the broader Wnt biology literature, and targets a pathway no FDA-approved treatment specifically engages. The limitations are real: small industry-associated trials, no independent replication, 16-week duration, and an unresolved long-term safety question stemming from the pathway’s oncogenic associations. That combination of genuine promise and genuine uncertainty is exactly what the pilot data evidence tier means.

  • PTD-DBM is a cell-penetrating peptide (PTD domain) fused to a Dishevelled binding sequence (DBM domain) that activates Wnt/β-catenin signaling in dermal papilla cells, promoting the telogen-to-anagen transition suppressed in androgenetic alopecia.
  • Evidence tier: pilot data. Published PubMed-indexed RCTs showing non-inferiority to minoxidil 3% at 16 weeks. Industry-associated; not independently replicated. Best human evidence of any hair peptide in this cluster.
  • The Wnt/β-catenin pathway is independently well-validated as the correct biological target for AGA — the compound’s mechanism aligns directly with the established pathophysiology of DHT-mediated follicle miniaturization.
  • Topical application twice daily at 3–5% in an aqueous leave-on solution is the evidence-based protocol. The PTD cell-penetrating sequence provides delivery advantage over passive topical peptides but does not eliminate the scalp penetration challenge.
  • Scalp microneedling (0.5–1.0 mm stamp) + topical PTD-DBM is the most popular advanced community protocol; mechanistically compelling given dermal papilla target depth; no specific trial data.
  • Combination with minoxidil: additive benefit shown in published trial. Combination with finasteride: mechanistically rational (DHT suppression upstream, Wnt activation downstream) but unstudied.
  • Safety: acceptable short-term profile in published trials. Theoretical long-term concern: Wnt/β-catenin’s role in oncogenesis warrants monitoring in extended use, particularly in individuals with relevant cancer history. Long-term data does not exist.
  • WADA: not prohibited. Not FDA approved. Available in some compounded formulations. Evom Inc. holds key intellectual property.

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

Selected References and Key Studies

  1. Kwack MH, et al. Dihydrotestosterone-inducible Dickkopf 1 from balding dermal papilla cells causes apoptosis in follicular keratinocytes. J Invest Dermatol. 2008;128(2):262–9. PMID 17914449 — Wnt/Dkk1 pathway in AGA pathophysiology
  2. Kim YS, et al. A cell-penetrating peptide, Dishevelled binding motif activates Wnt/β-catenin signaling and promotes the growth of hair follicles. Biochem Biophys Res Commun. 2010. — PTD-DBM mechanistic characterization
  3. Choi N, et al. Minoxidil reverses histone deacetylase-associated alopecia and generates hair regeneration by epigenetic regulation of hair-related genes and Wnt/β-catenin signaling. Biomolecules. 2021. PMID 34572597 — Wnt pathway context for minoxidil comparison
  4. Lim YY, et al. PTD-DBM topical solution for androgenetic alopecia: a randomized controlled trial versus minoxidil 3%. J Dermatol Sci. 2019. — Primary human trial reference
  5. Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell. 2012;149(6):1192–205. PMID 22682243 — comprehensive Wnt biology and oncology context
  6. Millar SE. Molecular mechanisms regulating hair follicle development. J Invest Dermatol. 2002;118(2):216–25. PMID 11841537 — foundational follicle development and Wnt biology

Further Reading

Disclaimer

This article is produced for educational and research purposes only. Peptidings does not provide medical advice, diagnosis, or treatment recommendations. Hair loss has multiple causes; nothing here should be interpreted as a recommendation to use any compound for hair loss treatment.

PTD-DBM is not FDA-approved. Published human trial data is limited to small industry-associated studies. The Wnt/β-catenin pathway’s associations with oncogenesis represent a theoretical long-term safety consideration that has not been resolved in published data. Individuals with personal or family history of Wnt-pathway-associated cancers should consult a physician before use.

All citations link to primary sources. Readers are encouraged to evaluate the evidence independently and consult a qualified dermatologist before making treatment decisions.

Resources & Further Research

Where to Go From Here

The services below have been selected by the Peptidings editorial team as resources worth your time, based on evidence standards, clinical oversight, and relevance to the compound covered above.

Affiliate disclosure: Peptidings may earn a commission if you purchase or subscribe through these links, at no cost to you. This never influences our evidence assessments, evidence tier classifications, or editorial coverage. Full disclosure policy →

Telehealth Options

Happy Head

A telehealth platform founded by board-certified dermatologists specializing in hair loss. Offers custom-compounded topical and oral treatments including finasteride, dutasteride, and minoxidil combinations — prescribed and personalized by physicians, delivered to your door.

View Treatment Options →

All links above are affiliate links. We may earn a commission if you subscribe, at no cost to you.

Scroll to Top